Cargando…
Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial
INTRODUCTION: Modern systemic treatment has reduced incidence of regional recurrences and improved survival in breast cancer (BC). It is thus questionable whether regional radiotherapy (RT) is still beneficial in patients with sentinel lymph node (SLN) macrometastasis. Postoperative regional RT is a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533703/ https://www.ncbi.nlm.nih.gov/pubmed/37751948 http://dx.doi.org/10.1136/bmjopen-2023-075543 |
_version_ | 1785112238418296832 |
---|---|
author | Alkner, Sara de Boniface, Jana Lundstedt, Dan Mjaaland, Ingvil Ryden, Lisa Vikstrom, Johan Bendahl, Pär-Ola Holmberg, Erik Sackey, Helena Wieslander, Elinore Karlsson, Per |
author_facet | Alkner, Sara de Boniface, Jana Lundstedt, Dan Mjaaland, Ingvil Ryden, Lisa Vikstrom, Johan Bendahl, Pär-Ola Holmberg, Erik Sackey, Helena Wieslander, Elinore Karlsson, Per |
author_sort | Alkner, Sara |
collection | PubMed |
description | INTRODUCTION: Modern systemic treatment has reduced incidence of regional recurrences and improved survival in breast cancer (BC). It is thus questionable whether regional radiotherapy (RT) is still beneficial in patients with sentinel lymph node (SLN) macrometastasis. Postoperative regional RT is associated with an increased risk of arm morbidity, pneumonitis, cardiac disease and secondary cancer. Therefore, there is a need to individualise regional RT in relation to the risk of recurrence. METHODS AND ANALYSIS: In this multicentre, prospective randomised trial, clinically node-negative patients with oestrogen receptor-positive, HER2-negative BC and 1-2 SLN macrometastases are eligible. Participants are randomly assigned to receive regional RT (standard arm) or not (intervention arm). Regional RT includes the axilla level I–III, the supraclavicular fossa and in selected patients the internal mammary nodes. Both groups receive RT to the remaining breast. Chest-wall RT after mastectomy is given in the standard arm, but in the intervention arm only in cases of widespread multifocality according to national guidelines. RT quality assurance is an integral part of the trial. The trial aims to include 1350 patients between March 2023 and December 2028 in Sweden and Norway. Primary outcome is recurrence-free survival (RFS) at 5 years. Non-inferiority will be declared if outcome in the de-escalation arm is not >4.5 percentage units below that with regional RT, corresponding to an HR of 1.41 assuming 88% 5-year RFS with standard treatment. Secondary outcomes include locoregional recurrence, overall survival, patient-reported arm morbidity and health-related quality of life. Gene expression analysis and tumour tissue-based studies to identify prognostic and predictive markers for benefit of regional RT are included. ETHICS AND DISSEMINATION: The trial protocol is approved by the Swedish Ethics Authority (Dnr-2022-02178-01, 2022-05093-02, 2023-00826-02, 2023-03035-02). Results will be presented at scientific conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05634889. |
format | Online Article Text |
id | pubmed-10533703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-105337032023-09-29 Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial Alkner, Sara de Boniface, Jana Lundstedt, Dan Mjaaland, Ingvil Ryden, Lisa Vikstrom, Johan Bendahl, Pär-Ola Holmberg, Erik Sackey, Helena Wieslander, Elinore Karlsson, Per BMJ Open Oncology INTRODUCTION: Modern systemic treatment has reduced incidence of regional recurrences and improved survival in breast cancer (BC). It is thus questionable whether regional radiotherapy (RT) is still beneficial in patients with sentinel lymph node (SLN) macrometastasis. Postoperative regional RT is associated with an increased risk of arm morbidity, pneumonitis, cardiac disease and secondary cancer. Therefore, there is a need to individualise regional RT in relation to the risk of recurrence. METHODS AND ANALYSIS: In this multicentre, prospective randomised trial, clinically node-negative patients with oestrogen receptor-positive, HER2-negative BC and 1-2 SLN macrometastases are eligible. Participants are randomly assigned to receive regional RT (standard arm) or not (intervention arm). Regional RT includes the axilla level I–III, the supraclavicular fossa and in selected patients the internal mammary nodes. Both groups receive RT to the remaining breast. Chest-wall RT after mastectomy is given in the standard arm, but in the intervention arm only in cases of widespread multifocality according to national guidelines. RT quality assurance is an integral part of the trial. The trial aims to include 1350 patients between March 2023 and December 2028 in Sweden and Norway. Primary outcome is recurrence-free survival (RFS) at 5 years. Non-inferiority will be declared if outcome in the de-escalation arm is not >4.5 percentage units below that with regional RT, corresponding to an HR of 1.41 assuming 88% 5-year RFS with standard treatment. Secondary outcomes include locoregional recurrence, overall survival, patient-reported arm morbidity and health-related quality of life. Gene expression analysis and tumour tissue-based studies to identify prognostic and predictive markers for benefit of regional RT are included. ETHICS AND DISSEMINATION: The trial protocol is approved by the Swedish Ethics Authority (Dnr-2022-02178-01, 2022-05093-02, 2023-00826-02, 2023-03035-02). Results will be presented at scientific conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05634889. BMJ Publishing Group 2023-09-26 /pmc/articles/PMC10533703/ /pubmed/37751948 http://dx.doi.org/10.1136/bmjopen-2023-075543 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Oncology Alkner, Sara de Boniface, Jana Lundstedt, Dan Mjaaland, Ingvil Ryden, Lisa Vikstrom, Johan Bendahl, Pär-Ola Holmberg, Erik Sackey, Helena Wieslander, Elinore Karlsson, Per Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title | Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title_full | Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title_fullStr | Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title_full_unstemmed | Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title_short | Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
title_sort | protocol for the t-rex-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533703/ https://www.ncbi.nlm.nih.gov/pubmed/37751948 http://dx.doi.org/10.1136/bmjopen-2023-075543 |
work_keys_str_mv | AT alknersara protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT debonifacejana protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT lundstedtdan protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT mjaalandingvil protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT rydenlisa protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT vikstromjohan protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT bendahlparola protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT holmbergerik protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT sackeyhelena protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT wieslanderelinore protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial AT karlssonper protocolforthetrextrialtailoredregionalexternalbeamradiotherapyinclinicallynodenegativebreastcancerpatientswith12sentinelnodemacrometastasesanopenmulticentrerandomisednoninferiorityphase3trial |